X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs CADILA HEALTHCARE - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA CADILA HEALTHCARE SUN PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 37.9 19.5 194.4% View Chart
P/BV x 4.0 4.6 87.5% View Chart
Dividend Yield % 0.3 0.9 35.2%  

Financials

 SUN PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
CADILA HEALTHCARE
Mar-18
SUN PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs701558 125.5%   
Low Rs433362 119.8%   
Sales per share (Unadj.) Rs110.4116.3 94.9%  
Earnings per share (Unadj.) Rs11.017.9 61.4%  
Cash flow per share (Unadj.) Rs17.223.1 74.5%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.40.8 46.3%  
Book value per share (Unadj.) Rs158.885.4 185.9%  
Shares outstanding (eoy) m2,399.261,023.74 234.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.0 129.9%   
Avg P/E ratio x51.625.7 200.7%  
P/CF ratio (eoy) x32.919.9 165.5%  
Price / Book Value ratio x3.65.4 66.3%  
Dividend payout %18.219.6 93.0%   
Avg Mkt Cap Rs m1,360,021470,664 289.0%   
No. of employees `00017.811.8 150.5%   
Total wages/salary Rs m53,67118,545 289.4%   
Avg. sales/employee Rs Th14,890.910,072.7 147.8%   
Avg. wages/employee Rs Th3,017.11,569.1 192.3%   
Avg. net profit/employee Rs Th1,480.61,547.7 95.7%   
INCOME DATA
Net Sales Rs m264,895119,049 222.5%  
Other income Rs m8,3881,132 741.0%   
Total revenues Rs m273,282120,181 227.4%   
Gross profit Rs m56,08128,475 196.9%  
Depreciation Rs m14,9985,388 278.4%   
Interest Rs m5,176911 568.1%   
Profit before tax Rs m44,29523,308 190.0%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4525,644 149.8%   
Profit after tax Rs m26,33818,292 144.0%  
Gross profit margin %21.223.9 88.5%  
Effective tax rate %19.124.2 78.8%   
Net profit margin %9.915.4 64.7%  
BALANCE SHEET DATA
Current assets Rs m316,35982,005 385.8%   
Current liabilities Rs m198,64360,720 327.1%   
Net working cap to sales %44.417.9 248.5%  
Current ratio x1.61.4 117.9%  
Inventory Days Days9573 129.6%  
Debtors Days Days10898 109.5%  
Net fixed assets Rs m213,17883,703 254.7%   
Share capital Rs m2,3991,024 234.3%   
"Free" reserves Rs m378,60686,421 438.1%   
Net worth Rs m381,00687,445 435.7%   
Long term debt Rs m17,72125,551 69.4%   
Total assets Rs m643,028180,653 355.9%  
Interest coverage x9.626.6 36.0%   
Debt to equity ratio x00.3 15.9%  
Sales to assets ratio x0.40.7 62.5%   
Return on assets %4.910.6 46.1%  
Return on equity %6.920.9 33.0%  
Return on capital %10.022.0 45.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81642,683 95.6%   
Fx outflow Rs m30,14311,242 268.1%   
Net fx Rs m10,67331,441 33.9%   
CASH FLOW
From Operations Rs m39,0729,193 425.0%  
From Investments Rs m-33,708-9,737 346.2%  
From Financial Activity Rs m-15,393515 -2,988.9%  
Net Cashflow Rs m-7,359-29 25,376.2%  

Share Holding

Indian Promoters % 63.7 74.8 85.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 8.3 61.8%  
FIIs % 23.0 5.9 389.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 11.0 75.5%  
Shareholders   133,026 44,069 301.9%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  DIVIS LABORATORIES  SANOFI INDIA  ALEMBIC PHARMA  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Sep 25, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - TTK HEALTHCARE COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS